Telix Pharmaceuticals US Inc.
Fishers, IN
- UEI
- NMRHMBK4YTH7
- CAGE
- 8CP27
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Telix Pharmaceuticals US Inc.
NMRHMBK4YTH7
- RLS (USA) Inc. UA3GDUKRYSM5
-
Telix Pharmaceuticals US Inc.
NMRHMBK4YTH7
- SAM.gov registration date
- Physical address
- 11700 Exit 5 Pkwy #200, Fishers, IN 46037, USA
- Website
- telixpharma.com
- Founded
- 2015
- Employees
- 251-1K
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| VA SAN diego psma | Veterans Integrated Service Network 22 | $496,000 | |
| Illuccix | Veterans Integrated Service Network 22 | $249,717 | |
| Illuccix | Veterans Integrated Service Network 8 | $1,750,000 | |
| Various radiopharmaceuticals OPT YR 1 | Veterans Integrated Service Network 9 | $857,500 | |
| Illuccix psma vasd | Veterans Integrated Service Network 22 | $538,575 |
About Telix Pharmaceuticals US Inc.
Telix Pharmaceuticals US Inc., a Fishers, Indiana-based manufacturer of radiopharmaceutical products, operates as a prime contractor supplying specialized nuclear medicine and diagnostic imaging agents to the Department of Veterans Affairs across multiple Veterans Integrated Service Networks. The company competes full-and-open without set-aside designations.
Telix's federal footprint centers on radiopharmaceutical supply under the GSA Federal Supply Schedule 65-IB (Pharmaceuticals and Drugs). The company manufactures two primary product lines for VA procurement: Illuccix, a radiopharmaceutical for prostate cancer imaging (PSMA-targeted), and Gozetotide, used for broader nuclear medicine diagnostic procedures. Representative awards include a $4.557 million firm fixed-price delivery order from Veterans Integrated Service Network 22 running through December 31, 2030, for radiopharmaceutical products in support of VA nuclear medicine and oncology imaging; a $1.75 million BPA call from Veterans Integrated Service Network 8 through September 2026 for Illuccix supply; and a $1.141 million BPA call from the same network through September 2025. Work is performed primarily at Telix's facilities in Fishers, Indiana, with secondary performance locations in Dublin, Ohio and Norcross, Georgia.
Customer concentration is extreme: the Department of Veterans Affairs accounts for 100% of the measured award footprint, with 95% of awards concentrated among five VA customer entities. The VA National Acquisition Center anchors the dollar value at $17.5 million through a single-award BPA for Illuccix procurement running through August 26, 2026. VISN 22 and VISN 9 follow with $7.5 million and $7.3 million in combined potential value respectively across eight and five awards. VISN 8 holds $2.9 million across two awards, and VISN 12 holds $325 thousand across three awards. Telix maintains three active IDVs under Schedule 65-IB: the $17.5 million Illuccix BPA awarded August 30, 2022; a $4.394 million BPA for various radiopharmaceuticals with VISN 9 running through September 30, 2028; and a $225 thousand multiple-award Federal Supply Schedule contract awarded August 15, 2022, through August 14, 2027. The 21 recorded task orders against these vehicles carry $39.4 million combined potential value.
Recent activity declined from seven awards in 2022 to two awards year-to-date in 2026, though the $4.557 million July 2026 delivery order from VISN 22 represents a material four-year commitment. Only two awards (combined potential value $2.6 million) face ultimate completion within the next twenty-four months, suggesting minimal near-term recompete exposure. Telix obligated $8.3 million across its $35.6 million combined potential value, indicating active consumption of BPA and schedule capacity. The corporate structure includes a named subsidiary, RLS (USA) Inc., which the source does not characterize separately. The vendor operates exclusively as a prime contractor with no recorded subcontract engagement.
Contract vehicles
Quick answers
What is Telix Pharmaceuticals US Inc.'s UEI?
Telix Pharmaceuticals US Inc.'s Unique Entity ID (UEI) in SAM.gov is NMRHMBK4YTH7.
What is Telix Pharmaceuticals US Inc.'s CAGE code?
Telix Pharmaceuticals US Inc.'s CAGE code is 8CP27.
What is Telix Pharmaceuticals US Inc.'s primary NAICS code?
Telix Pharmaceuticals US Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Telix Pharmaceuticals US Inc. located?
Telix Pharmaceuticals US Inc.'s physical address in SAM.gov is 11700 Exit 5 Pkwy #200, Fishers, IN 46037, USA.
Is Telix Pharmaceuticals US Inc. registered in SAM.gov?
Yes. Telix Pharmaceuticals US Inc.'s SAM.gov registration is active through January 30, 2027.
Which contract vehicles does Telix Pharmaceuticals US Inc. hold?
Telix Pharmaceuticals US Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Telix Pharmaceuticals US Inc.'s most recent federal award?
Telix Pharmaceuticals US Inc.'s most recent federal contract award is VA SAN diego psma (36C26226N0537), from Veterans Integrated Service Network 22, on July 1, 2026.
On GovTribe
See Telix Pharmaceuticals US Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors